Celgene (CELG)

Company Description

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.


86 Morris Avenue
Summit, NJ 07901
United States



Get BioInvest's perspective on Celgene's CEO

Latest Company News

Celgene Corporation (NASDAQ:CELG) Spectacular Growth Potential Makes It a ... Library For Smart Investors - 9 hours ago Celgene Corporation (NASDAQ:CELG) shares are gaining value in 2017 amid the company's strong growth prospects and attractive pipeline. High Expectations For Celgene Corporation (NASDAQ:CELG), But Is There Upside? - Midway Monitor UBS Initiated its coverage for Celgene Corporation (CELG) - StandardOracle [...]
Fri, Mar 24, 2017 4:41:00 PM, Continue reading at the source
How Does the Chart Look for Celgene Corporation (CELG) ? The USA Commerce - 13 hours ago We have gathered the technical data on Celgene Corporation (CELG), and see some interesting trends in the stock's behavior of late. [...]
Fri, Mar 24, 2017 12:45:00 PM, Continue reading at the source
Celgene: In Breakout Mode? Seeking Alpha - Mar 16, 2017 Biotech stalwart Celgene touched $140 in the early summer of 2015 just before a bear market swept over the biotech sector. With sentiment on this area of the market improving and this biotech juggernaut continuing to execute, shares touched a one year ... [...]
Thu, Mar 16, 2017 3:45:00 PM, Continue reading at the source
Celgene Corporation's (CELG) Management Presents at Barclays Global Healthcare ... Seeking Alpha - Mar 15, 2017 Okay, welcome to the second day of the Barclays Global Healthcare Conference. My name is Geoff Meacham. I'm the Senior Biopharma Analyst. [...]
Wed, Mar 15, 2017 8:20:00 PM, Continue reading at the source
Celgene Clarifies Matters At The Cowen Conference; Takeaways Seeking Alpha - Mar 10, 2017 The main questions have been the prospects to replace Revlimid sales next decade, and whether ozanimod for MS could be a blockbuster. Celgene Co. (CELG) Downgraded by Zacks Investment Research to Hold - Sports Perspectives [...]
Fri, Mar 10, 2017 7:07:00 PM, Continue reading at the source
Celgene Corporation (CELG) Stock Is Staging a Tempting Breakout Investorplace.com - Mar 10, 2017 If there was ever a doubt, the latest price action in Celgene Corporation (NASDAQ:CELG) should help ease those fears and usher in more investor cheer in the coming weeks. [...]
Fri, Mar 10, 2017 5:12:00 PM, Continue reading at the source
Celgene: A Growth Stock You Don't Want To Miss Seeking Alpha - Mar 10, 2017 The company operates in more than 60 countries and sells its products in more than 70. In 2016, Celgene generated sales of $11.2 billion. [...]
Fri, Mar 10, 2017 2:48:00 PM, Continue reading at the source
Celgene Corp Presents Cowen Health Care Broker Conference (CELG) (Transcript) Seeking Alpha - Mar 8, 2017 Good morning, everyone. My name is Eric Schmidt, and on behalf of the Cowen team I want to welcome you back to our 37th Annual Healthcare Conference, day three. Celgene Adds To Wednesday's Gain - Benzinga [...]
Wed, Mar 08, 2017 8:03:00 PM, Continue reading at the source
Celgene Announces Oral OTEZLA Demonstrated Significant Improvement vs Placebo ... Benzinga - Mar 5, 2017 Celgene Corporation (NASDAQ: CELG) today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate plaque psoriasis with a ... [...]
Sun, Mar 05, 2017 5:37:00 PM, Continue reading at the source
Celgene: A 'Fuggedaboutit' Core Biotech Holding Seeking Alpha - Feb 23, 2017 Few large-cap biotech concerns have a clearer earnings and revenue growth trajectory over the next 3-5 years than Celgene. It has a blockbuster blood cancer drug, several other solid compounds in its product portfolio, a deep pipeline, and dozens of ... [...]
Thu, Feb 23, 2017 5:48:00 PM, Continue reading at the source